Cardiac ArrhythmiaNCT04463524
Screening for Hearth Rhythm Disorders
An observational study of Cardiac Arrhythmia, run by Healthcare Center Murska Sobota at 1 site in Slovenia.
Trial summary
This study aimed to analyze the usefulness of telecardiology in the primary health care level using an ECG personal sensor developed in Slovenia.Investigators also wanted to evaluate the satisfaction of patients and their physicians and the cost-effectiveness of this tool. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiac Arrhythmia
- What is being tested?
- Personal ECG digital sensor
- Type of treatment
- Medical device
- How many people
- 130 participants
- Where
- 1 siteSlovenia
- Study dates
- Oct 2016to Aug 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients who come to their family physician with the complaint of hearth rhythm disorder as selected time. Their family physicians are also included.
Who may be able to join
- age over 18 years,
- there was a history of suspected arrhythmia,
- at the time of examination, the ECG is within normal limits
- the patient has never been treated for any heart rhythm disorder.
Who cannot join
- age less than 18 years,
- on examination on the ECG, the patient was not in sinus rhythm, and
- that the patient has a known heart rhythm disorder and / or is being treated for it.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Screening of Patients With Suspected Heart Rhythm Disorder on Primary Health Care Level With the Use of Personal Digital ECG Sensor
This study aimed to analyze the usefulness of telecardiology in the primary health care level using an ECG personal sensor developed in Slovenia.Investigators also wanted to evaluate the satisfaction of patients and their physicians and the cost-effectiveness of this tool.
Read the detailed description
This observational prospective cohort study was conducted on patients with a history of rhythm disturbance who visited their family physician at the Health Care Center of Ljubljana and Health Care Center of Murska Sobota from October 2016 to January 2018. It included family physicians and their patients and was conducted on two levels. The inclusion criteria were age of ≥18 years, suspected heart rhythm disorder, and no previous diagnosis of rhythm disorder. Patients had a 12-channel ECG record performed at the first visit. If a rhythm disturbance was detected at that time, the patient was treated according to the guidelines and was not included in the study. However, if a diagnosis of rhythm disorder could not have been made, the patient was included in the study. In the study, the investigators divided participants into two groups: the test group and control group, where the patients in the test group received a wearable device. The pilot study is a part of an ongoing study that includes a bigger sample calculated with the help of Raosoft sample size calculator. Investigators estimated that a sample size of 100 patients (50 in test and 50 in the control group) is sufficient to obtain relevant data in the population. Patients who met these criteria were invited to participate in a study that was approved by the Ethics Committee of the Republic of Slovenia (number 0120-299/2017-7, KME 47/06/17), and written informed consent confirmed their participation. The study was conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).
In collaboration with medical experts, the Jožef Stefan Institute of Slovenia developed a personal portable ECG sensor that works in conjunction with a smartphone. The Personal Digital Mobile Body Sensor is listed in the medical device category, has the status of a medical device with all necessary certifications, and is owned by Savvy. It includes a personal sensor, ECG electrode kit, MobECG mobile application, and computer program called VisECG, which is currently available for Android only. The ECG sensor consists of two electrodes, which are placed 8.5 cm apart, and measures the potential between these two closely placed body-surface electrodes. The gadget weighs 21 g and has several possible positions of placement. The measurement is transmitted via Bluetooth connection to a smartphone, where the device is paired and managed via the MobECG mobile application. Initially, personal and other necessary information are entered into the smartphone application; then, the user can forget that he or she is wearing the device. The application works reliably in the background, even when using the phone for calls or other applications. If desired, the user can monitor the heart rate on the meter display with a curve and calculate it on an ongoing basis. Finally, the measurements are collected on the phone and can be transmitted to the physician in two ways: (1) pressing the button, the user can prepare a PDF report and send it to the physician's e-mail address or (2) transfer the data via USB cable to the physician's computer, where he or she can closely monitor the entire recording using VisECG. The first method is useful in the case of a severe disorder in which it is necessary to inform the physician. However, it is still related to the availability and responsiveness of the physician. When reading the recording, one should remember that it is not any standard lead typically used in a Holter monitor and that it is a single-channel measurement that is performed live on a patient moving and performing daily activities. The recordings can show different disorders but need to be evaluated so that artefacts can be distinguished from the actual disturbance of the rhythm. VisECG enables us to review and accurately analyze the recording and produce a report that can be submitted to physicians of other specialities for consultation or delivered to the patient and his or her physician as a measurement result. Given that the measurement is only a single channel, we can estimate the frequency and possible disturbances of rhythm but not ischemia.The study included the patients and their family physician. Patients with a complaint of heart rhythm disorder but no detectable rhythm disturbance on a 12-channel ECG record performed at the first visit were included. If a rhythm disturbance was detected at that time, the patient was treated according to the guidelines and was not included in the study. However, if a diagnosis of rhythm disorder could not have been made, the patient was included in the study. In the study, the investigators divided participants into two groups: test group where they received the personal ECG sensor and control group without the sensor one after another according to their visits at the office. However, the protocol was not followed rigorously, and physicians had the option of deciding for themselves if they prefer not to include the patient in the test group. The test group received an ECG sensor, which was placed by a healthcare professional and worn for three days. Whereat that time, they received information about the placement and handling of the sensor. The sensor was placed using two self-adhesive electrodes on the skin of the chest, which should not be too hairy. Then, the sensor was attached to the electrode and connected via Bluetooth to the smartphone, which was also provided to the patient with the charger for the duration of the examination. Patients were advised to perform their daily activities as regularly as possible and not to remove the sensor while showering or sleeping and keep the smartphone in the same room with them. In case the electrode peeled off, the patient had four spare electrodes and could install them himself. During the investigation, the patient kept a journal where he or she wrote down his or her problems and feelings. After 3 days, the patient returned to the healthcare provider, who removed the sensor and downloaded the measurements from the phone, which are then sent to the physicians who will analyze the reading. Then, the measurement was transferred to the computer memory and sent to the physicians for evaluation. The same patient underwent a checkup with the physician after 5-10 days, which depended on the date they had made an appointment. The physician read the recording, and in case of severe rhythm disorder, the patient was called earlier for a checkup at the physician's clinic where he or she received treatment as needed. The control group received a questionnaire and returned to the physician after 5-10 days.
For the purpose of the study, a questionnaire was made, and it was validated in a similar pilot study in a hospital setting. At the first visit to the doctor's office, all patients received a questionnaire to record their problems and provide an opinion on the quality and usefulness of the examination. Also, physicians of all tested patient had to complete two questionnaires. One for a patient on the first visit, then after 5-10 days, and after 3 months. The questionnaire provided us with demographics data, chronic illness and medication, presence of possible rhythm disorder and actions taken after first and second visit. The other questionnaire was used to record their comments on the quality and usefulness of this method.
- Conditions
- Cardiac Arrhythmia
- Being tested
- Personal ECG digital sensor
- Keywords
- Heart rhythm disorder, palpitation, primary healthcare, personal mobile ECG sensor, referral
- Medical subject headings
- Arrhythmias, Cardiac
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Personal ECG digital sensorDevice
Also called Savvy Personal ECG digital sensor
Patients in test group will receive personal ECG sensor and in control gropu will not.
| Study group | Role | What they receive |
|---|---|---|
| Test | They will receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken. Receives: Device: Personal ECG digital sensor | |
| Control | They will not receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken. Receives: Device: Personal ECG digital sensor |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from no detected hearth rhythm disorders to diagnosed hearth rhythm disorders at day 90
With the help of ECG sensor finding arrhythmias in patients where standard ECG record was normal. Change = (day 90 record - baseline record)
Measured: baseline and day 90
Secondary outcomes (1)
Change in patients and doctors satisfaction with this method after detecting possible hearth rhythm disorders
With the help of a questionnaire see how users are satisfied with this method after 3 months. Change = (day 90 record - baseline record)
Measured: baseline and day 90
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2020
- Study startOct 2016
- Primary completionJan 2018
- Study completionAug 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Cardiac ArrhythmiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 130 participants (actual)
Sponsor and investigators
- Lead sponsor
- Healthcare Center Murska Sobota
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Stasa Vodicka, Healthcare Center Murska Sobota
- Investigators
- Stasa Vodicka, MD, Principal investigator, Health care center Murska Sobota
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04463524
- Sponsor's protocol ID
- UESVADZ001
- Status last verified
- Jul 2020
- First submitted
- 22 Jun 2020
- Last updated
- 9 Jul 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mistry H. Systematic review of studies of the cost-effectiveness of telemedicine and telecare. Changes in the economic evidence over twenty years. J Telemed Telecare. 2012 Jan;18(1):1-6. doi: 10.1258/jtt.2011.110505. Epub 2011 Nov 18.
PubMed 22101609Lieberman J. How telemedicine is aiding prompt ECG diagnosis in primary care. Br J Community Nurs. 2008 Mar;13(3):123-6. doi: 10.12968/bjcn.2008.13.3.28676.
PubMed 18557568Orchard J, Freedman SB, Lowres N, Peiris D, Neubeck L. iPhone ECG screening by practice nurses and receptionists for atrial fibrillation in general practice: the GP-SEARCH qualitative pilot study. Aust Fam Physician. 2014 May;43(5):315-9.
PubMed 24791776Klein-Wiele O, Faghih M, Dreesen S, Urbien R, Abdelghafor M, Kara K, Schulte-Hermes M, Garmer M, Gronemeyer D, Hailer B. A novel cross-sector telemedical approach to detect arrhythmia in primary care patients with palpitations using a patient-activated event recorder. Cardiol J. 2016;23(4):422-8. doi: 10.5603/CJ.a2016.0033. Epub 2016 Jun 20.
PubMed 27320955
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Screening of Patients With Suspected Heart Rhythm Disorder on Primary Health Care Level With the Use of Personal Digital ECG Sensor
- ClinicalTrials.gov ID
- NCT04463524
- Acronym / sponsor ID
- UESVADZ001
- Conditions
- Cardiac Arrhythmia
- Keywords
- Heart rhythm disorder, palpitation, primary healthcare, personal mobile ECG sensor, referral
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 130 participants (actual)
- Lead sponsor
- Healthcare Center Murska SobotaUniversity, hospital or other
- Study start
- Oct 2016 (actual)
- Primary completion
- Jan 2018 (actual)
- Study completion
- Aug 2019 (actual)
- First posted
- 9 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to analyze the usefulness of telecardiology in the primary health care level using an ECG personal sensor developed in Slovenia.Investigators also wanted to evaluate the satisfaction of patients and their physicians and the cost-effectiveness of this tool.
Detailed description
This observational prospective cohort study was conducted on patients with a history of rhythm disturbance who visited their family physician at the Health Care Center of Ljubljana and Health Care Center of Murska Sobota from October 2016 to January 2018. It included family physicians and their patients and was conducted on two levels. The inclusion criteria were age of ≥18 years, suspected heart rhythm disorder, and no previous diagnosis of rhythm disorder. Patients had a 12-channel ECG record performed at the first visit. If a rhythm disturbance was detected at that time, the patient was treated according to the guidelines and was not included in the study. However, if a diagnosis of rhythm disorder could not have been made, the patient was included in the study. In the study, the investigators divided participants into two groups: the test group and control group, where the patients in the test group received a wearable device. The pilot study is a part of an ongoing study that includes a bigger sample calculated with the help of Raosoft sample size calculator. Investigators estimated that a sample size of 100 patients (50 in test and 50 in the control group) is sufficient to obtain relevant data in the population. Patients who met these criteria were invited to participate in a study that was approved by the Ethics Committee of the Republic of Slovenia (number 0120-299/2017-7, KME 47/06/17), and written informed consent confirmed their participation. The study was conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).
In collaboration with medical experts, the Jožef Stefan Institute of Slovenia developed a personal portable ECG sensor that works in conjunction with a smartphone. The Personal Digital Mobile Body Sensor is listed in the medical device category, has the status of a medical device with all necessary certifications, and is owned by Savvy. It includes a personal sensor, ECG electrode kit, MobECG mobile application, and computer program called VisECG, which is currently available for Android only. The ECG sensor consists of two electrodes, which are placed 8.5 cm apart, and measures the potential between these two closely placed body-surface electrodes. The gadget weighs 21 g and has several possible positions of placement. The measurement is transmitted via Bluetooth connection to a smartphone, where the device is paired and managed via the MobECG mobile application. Initially, personal and other necessary information are entered into the smartphone application; then, the user can forget that he or she is wearing the device. The application works reliably in the background, even when using the phone for calls or other applications. If desired, the user can monitor the heart rate on the meter display with a curve and calculate it on an ongoing basis. Finally, the measurements are collected on the phone and can be transmitted to the physician in two ways: (1) pressing the button, the user can prepare a PDF report and send it to the physician's e-mail address or (2) transfer the data via USB cable to the physician's computer, where he or she can closely monitor the entire recording using VisECG. The first method is useful in the case of a severe disorder in which it is necessary to inform the physician. However, it is still related to the availability and responsiveness of the physician. When reading the recording, one should remember that it is not any standard lead typically used in a Holter monitor and that it is a single-channel measurement that is performed live on a patient moving and performing daily activities. The recordings can show different disorders but need to be evaluated so that artefacts can be distinguished from the actual disturbance of the rhythm. VisECG enables us to review and accurately analyze the recording and produce a report that can be submitted to physicians of other specialities for consultation or delivered to the patient and his or her physician as a measurement result. Given that the measurement is only a single channel, we can estimate the frequency and possible disturbances of rhythm but not ischemia.The study included the patients and their family physician. Patients with a complaint of heart rhythm disorder but no detectable rhythm disturbance on a 12-channel ECG record performed at the first visit were included. If a rhythm disturbance was detected at that time, the patient was treated according to the guidelines and was not included in the study. However, if a diagnosis of rhythm disorder could not have been made, the patient was included in the study. In the study, the investigators divided participants into two groups: test group where they received the personal ECG sensor and control group without the sensor one after another according to their visits at the office. However, the protocol was not followed rigorously, and physicians had the option of deciding for themselves if they prefer not to include the patient in the test group. The test group received an ECG sensor, which was placed by a healthcare professional and worn for three days. Whereat that time, they received information about the placement and handling of the sensor. The sensor was placed using two self-adhesive electrodes on the skin of the chest, which should not be too hairy. Then, the sensor was attached to the electrode and connected via Bluetooth to the smartphone, which was also provided to the patient with the charger for the duration of the examination. Patients were advised to perform their daily activities as regularly as possible and not to remove the sensor while showering or sleeping and keep the smartphone in the same room with them. In case the electrode peeled off, the patient had four spare electrodes and could install them himself. During the investigation, the patient kept a journal where he or she wrote down his or her problems and feelings. After 3 days, the patient returned to the healthcare provider, who removed the sensor and downloaded the measurements from the phone, which are then sent to the physicians who will analyze the reading. Then, the measurement was transferred to the computer memory and sent to the physicians for evaluation. The same patient underwent a checkup with the physician after 5-10 days, which depended on the date they had made an appointment. The physician read the recording, and in case of severe rhythm disorder, the patient was called earlier for a checkup at the physician's clinic where he or she received treatment as needed. The control group received a questionnaire and returned to the physician after 5-10 days.
For the purpose of the study, a questionnaire was made, and it was validated in a similar pilot study in a hospital setting. At the first visit to the doctor's office, all patients received a questionnaire to record their problems and provide an opinion on the quality and usefulness of the examination. Also, physicians of all tested patient had to complete two questionnaires. One for a patient on the first visit, then after 5-10 days, and after 3 months. The questionnaire provided us with demographics data, chronic illness and medication, presence of possible rhythm disorder and actions taken after first and second visit. The other questionnaire was used to record their comments on the quality and usefulness of this method.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test | – | Device: Personal ECG digital sensorThey will receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken. |
| Control | – | Device: Personal ECG digital sensorThey will not receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who come to their family physician with the complaint of hearth rhythm disorder as selected time. Their family physicians are also included.
Key inclusion criteria (4 listed)
- age over 18 years,
- there was a history of suspected arrhythmia,
- at the time of examination, the ECG is within normal limits
- the patient has never been treated for any heart rhythm disorder.
Key exclusion criteria (3 listed)
- age less than 18 years,
- on examination on the ECG, the patient was not in sinus rhythm, and
- that the patient has a known heart rhythm disorder and / or is being treated for it.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Personal ECG digital sensorAlso: Savvy Personal ECG digital sensorPatients in test group will receive personal ECG sensor and in control gropu will not. | Device | Control, Test |
Primary outcome
Change from no detected hearth rhythm disorders to diagnosed hearth rhythm disorders at day 90
Time frame: baseline and day 90
With the help of ECG sensor finding arrhythmias in patients where standard ECG record was normal. Change = (day 90 record - baseline record)
1 secondary outcome
Change in patients and doctors satisfaction with this method after detecting possible hearth rhythm disorders
Time frame: baseline and day 90
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2020.
- Background: PubMed 22101609Mistry H. Systematic review of studies of the cost-effectiveness of telemedicine and telecare. Changes in the economic evidence over twenty years. J Telemed Telecare. 2012 Jan;18(1):1-6. doi: 10.1258/jtt.2011.110505. Epub 2011 Nov 18.
- Results publication: PubMed 18557568Lieberman J. How telemedicine is aiding prompt ECG diagnosis in primary care. Br J Community Nurs. 2008 Mar;13(3):123-6. doi: 10.12968/bjcn.2008.13.3.28676.
- Results publication: PubMed 24791776Orchard J, Freedman SB, Lowres N, Peiris D, Neubeck L. iPhone ECG screening by practice nurses and receptionists for atrial fibrillation in general practice: the GP-SEARCH qualitative pilot study. Aust Fam Physician. 2014 May;43(5):315-9.
- Results publication: PubMed 27320955Klein-Wiele O, Faghih M, Dreesen S, Urbien R, Abdelghafor M, Kara K, Schulte-Hermes M, Garmer M, Gronemeyer D, Hailer B. A novel cross-sector telemedical approach to detect arrhythmia in primary care patients with palpitations using a patient-activated event recorder. Cardiol J. 2016;23(4):422-8. doi: 10.5603/CJ.a2016.0033. Epub 2016 Jun 20.
- Use of personal digital ECG sensorLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Cardiac Arrhythmia
RecruitingObservational study
BOdygUardian MOnitoriNg for ReCurrencE of AF
Atrial Fibrillation (AF)
Active, not recruiting
Safety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation
Atrial Fibrillation (Paroxysmal)
Active, not recruitingObservational study
Resumption of Anticoagulation After Major Gastrointestinal Bleeding in Patients With Atrial Fibrillation
Atrial Fibrillation (AF), Gastrointestinal Bleeding
Recruiting
A Comparison of Pulsed Field Ablation (PFA) vs Cryoablation for Atrial Fibrillation Under Deep Sedation
Atrial Fibrillation (AF)
Not yet recruiting
CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stasa Vodicka, MD principal investigator
Health care center Murska Sobota
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiac Arrhythmia, run by Healthcare Center Murska Sobota at 1 site in Slovenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from no detected hearth rhythm disorders to diagnosed hearth rhythm disorders at day 90 (time frame: baseline and day 90). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04463524, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2020.